15.48
0.03 (0.16%)
| Previous Close | 15.45 |
| Open | 15.50 |
| Volume | 298,770 |
| Avg. Volume (3M) | 1,478,606 |
| Market Cap | 2,058,966,912 |
| Price / Earnings (TTM) | 6.79 |
| Price / Earnings (Forward) | 17.64 |
| Price / Sales | 6.76 |
| Price / Book | 3.34 |
| 52 Weeks Range |
| Profit Margin | 16.11% |
| Operating Margin (TTM) | 37.43% |
| Diluted EPS (TTM) | 0.270 |
| Quarterly Revenue Growth (YOY) | 24.20% |
| Total Debt/Equity (MRQ) | 22.25% |
| Current Ratio (MRQ) | 5.93 |
| Operating Cash Flow (TTM) | 64.29 M |
| Levered Free Cash Flow (TTM) | 47.49 M |
| Return on Assets (TTM) | 5.20% |
| Return on Equity (TTM) | 11.23% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Aurinia Pharmaceuticals Inc | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -2.0 |
| Average | -0.33 |
|
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 9.07% |
| % Held by Institutions | 47.53% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tang Capital Management Llc | 31 Mar 2026 | 12,893,814 |
| Nea Management Company, Llc | 31 Mar 2026 | 3,969,834 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |